Spots Global Cancer Trial Database for genital neoplasms, male
Every month we try and update this database with for genital neoplasms, male cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study of Ixabepilone Before Surgery for High-Risk Localized Prostate Cancer | NCT00672009 | Prostatic Disea... Genital Neoplas... Urogenital Neop... Genital Disease... Adenocarcinoma Prostatic Neopl... Neoplasms, Glan... Carcinoma | Ixabepilone | - | Cedars-Sinai Medical Center | |
| Trial of NanoPac Focal Therapy for Prostate Cancer | NCT04221828 | Prostate Cancer Prostate Adenoc... Prostate Cancer... Prostatic Neopl... Urogenital Neop... Genital Neoplas... Localized Cance... | NanoPac (steril... | 18 Years - | NanOlogy, LLC | |
| Stereotactic Body Radiation Therapy (SBRT) for Prostate Cancer | NCT01540994 | Prostatic Neopl... | radiation thera... | 50 Years - 90 Years | Sharp HealthCare | |
| Protection of Rectum From High Radiation Doses Using a Spacer | NCT01918605 | Prostatic Neopl... Genital Neoplas... Urogenital Neop... Neoplasms by Si... | Diluted spacer Non-diluted spa... | 50 Years - 78 Years | University of Oulu | |
| P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC) | NCT04249947 | Prostatic Neopl... Neoplasms by Hi... Neoplasms, Pros... Prostate Cancer Metastatic Cast... Neoplasms Prostatic Neopl... Genital Neoplas... Urogenital Neop... Neoplasms by Si... Prostatic Disea... Salivary Gland ... Salivary Gland ... Adenoid Cystic ... Salivary Duct C... Mucoepidermoid ... Acinic Cell Tum... | P-PSMA-101 CAR-... Rimiducid | 18 Years - | Poseida Therapeutics, Inc. | |
| Evaluation of Length and Quality of Prostate Biopsies Taken by a New Biopsy Needle | NCT04880681 | Prostate Cancer... | Novel needle (1... Standard Tru Cu... | 40 Years - | Region Skane | |
| [Ac-225]-PSMA-62 Trial in Biochemically Recurrent and Metastatic Castration Resistant Prostate Cancer | NCT06229366 | Prostate Cancer Metastatic Cast... Biochemically R... | [Ac-225]-PSMA-6... [Ac-225]-PSMA-6... | 18 Years - | POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company | |
| High Resolution, 18F-PSMA PET-MRI Before Prostate Cancer HIFU or Radical Prostatectomy | NCT04461509 | Prostatic Neopl... Genital Neoplas... Urogenital Neop... Neoplasms by Si... Neoplasms Genital Disease... Prostatic Disea... | 18F-PSMA | 18 Years - | Cedars-Sinai Medical Center | |
| Pembrolizumab in Subjects With Incurable Platinum-Refractory Germ Cell Tumors | NCT02499952 | Germ Cell Neopl... Testicular Neop... Non Seminomatou... Mediastinal Neo... Genital Neoplas... Genital Neoplas... Ovarian Neoplas... | Pembrolizumab | 18 Years - | Hoosier Cancer Research Network | |
| EVOLUTION: 177Lu-PSMA Therapy Versus 177Lu-PSMA in Combination With Ipilimumab and Nivolumab for Men With mCRPC | NCT05150236 | Prostatic Neopl... Genital Neoplas... Urogenital Neop... Prostate Cancer Neoplasms by Si... Neoplasms Prostatic Disea... | 177Lu-PSMA-617 Ipilimumab Nivolumab | 18 Years - | Australian and New Zealand Urogenital and Prostate Cancer Trials Group | |
| Stereotactic Body Radiation Therapy (SBRT) for Prostate Cancer | NCT01540994 | Prostatic Neopl... | radiation thera... | 50 Years - 90 Years | Sharp HealthCare | |
| [Ac-225]-PSMA-62 Trial in Biochemically Recurrent and Metastatic Castration Resistant Prostate Cancer | NCT06229366 | Prostate Cancer Metastatic Cast... Biochemically R... | [Ac-225]-PSMA-6... [Ac-225]-PSMA-6... | 18 Years - | POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company | |
| CATCH-R: A Rollover Study to Provide Continued Access to Rucaparib | NCT04676334 | Metastatic Cast... Ovarian Cancer Epithelial Ovar... Fallopian Tube ... Peritoneal Canc... Other Solid Tum... | Rucaparib | 18 Years - | pharmaand GmbH | |
| Prostate Cancer Stereotactic Radiotherapy | NCT02319239 | Prostate Neopla... Toxicity Due to... | Fractionation hypofractionate... stereotactic fr... | 30 Years - | Tampere University Hospital | |
| Study of 225Ac-PSMA-617 in Men With PSMA-positive Prostate Cancer | NCT04597411 | Prostatic Neopl... | 225^Ac-PSMA-617 68^Ga-PSMA-11 | 18 Years - | Endocyte | |
| A JNJ-56021927 (ARN-509; Apalutamide) QT/QTc Study | NCT02578797 | Castration-Resi... | Apalutamide | 18 Years - | Aragon Pharmaceuticals, Inc. | |
| Glivec in Prostate Cancer Patients With Rising PSA Following Radical Prostectomy | NCT01316458 | Prostatic Neopl... Genital Neoplas... Neoplasms, Abdo... Urogenital Neop... Genital Disease... Prostatic Disea... Antineoplastic ... Imatinib | STI571 (GlivecĀ®... | 18 Years - | Novartis | |
| A Study of MK4827 in Participants With Advanced Solid Tumors or Hematologic Malignancies (MK-4827-001 AM8) | NCT00749502 | Solid Tumors Chronic Lymphoc... T-cell-prolymph... | MK-4827 | 18 Years - | Tesaro, Inc. | |
| A Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects With Advanced Solid Tumors and Subsequent Dose Expansion Cohorts | NCT02266745 | Advanced Solid ... CRPC mCRPC Metastatic Cast... PT-112 Prostatic Neopl... Genital Neoplas... Urogenital Neop... Neoplasms by Si... | PT-112 Injectio... | 18 Years - | Promontory Therapeutics Inc. | |
| A Study of ARV-766 Given by Mouth in Men With Metastatic Prostate Cancer | NCT05067140 | Prostate Cancer... | ARV-766 Part A&... ARV-766 + Abira... | 18 Years - | Arvinas Inc. | |
| Health Gatherings - For Your Health After Cancer | NCT03344757 | Prostate Neopla... Genital Neoplas... Urogenital Neop... Neoplasm, Prost... Genital Disease... Prostatic Disea... | Cultural CBSM Standard CBSM | 18 Years - | University of Miami | |
| Sequencing of Sipuleucel-T and ADT in Men With Non-metastatic Prostate Cancer | NCT01431391 | Prostatic Neopl... Prostate Cancer Prostatic Adeno... | sipuleucel-T leuprolide acet... | 18 Years - | Dendreon | |
| Phase 2 Study of Association Gemcitabine-Cisplatin to Treat Penis Epidermoid Carcinoma | NCT00210041 | Genital Neoplas... | Gemcitabine Cisplatin | 18 Years - | Institut Claudius Regaud | |
| Study of Abiraterone Acetate in Patients With Advanced Prostate Cancer | NCT01217697 | Prostate Neopla... Genital Neoplas... Urogenital Neop... Genital Disease... | Abiraterone Ace... Prednisone\Pred... | 18 Years - 99 Years | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | |
| Glivec in Prostate Cancer Patients With Rising PSA Following Radical Prostectomy | NCT01316458 | Prostatic Neopl... Genital Neoplas... Neoplasms, Abdo... Urogenital Neop... Genital Disease... Prostatic Disea... Antineoplastic ... Imatinib | STI571 (GlivecĀ®... | 18 Years - | Novartis | |
| Prostate Cancer Stereotactic Radiotherapy | NCT02319239 | Prostate Neopla... Toxicity Due to... | Fractionation hypofractionate... stereotactic fr... | 30 Years - | Tampere University Hospital | |
| EVOLUTION: 177Lu-PSMA Therapy Versus 177Lu-PSMA in Combination With Ipilimumab and Nivolumab for Men With mCRPC | NCT05150236 | Prostatic Neopl... Genital Neoplas... Urogenital Neop... Prostate Cancer Neoplasms by Si... Neoplasms Prostatic Disea... | 177Lu-PSMA-617 Ipilimumab Nivolumab | 18 Years - | Australian and New Zealand Urogenital and Prostate Cancer Trials Group | |
| Evaluation of Length and Quality of Prostate Biopsies Taken by a New Biopsy Needle | NCT04880681 | Prostate Cancer... | Novel needle (1... Standard Tru Cu... | 40 Years - | Region Skane | |
| A Study of ARV-766 Given by Mouth in Men With Metastatic Prostate Cancer | NCT05067140 | Prostate Cancer... | ARV-766 Part A&... ARV-766 + Abira... | 18 Years - | Arvinas Inc. | |
| Phase 1-2 Study of Onapristone in Patients With Advanced Castration-resistant Prostate Cancer | NCT02049190 | Prostate Cancer Metastatic Pros... Androgen-indepe... Recurrent Prost... | onapristone abiraterone | 18 Years - | Arno Therapeutics | |
| Trial of NanoPacĀ® Focal Therapy in Subjects With Prostate Cancer | NCT03077659 | Adenocarcinoma ... | NanoPacĀ® | 18 Years - | NanOlogy, LLC |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
